Keywords: PCSK9; FOURIER; GLAGOV; CANTOS;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Familial hypercholesterolemia; Lipids; LDL; Atherosclerosis; Statins; PCSK9;
Keywords: Familial hypercholesterolemia; FH; Universal screening; Cascade screening; Children; Cholesterol; Hypercholesterolemia; Next-generation sequencing; Genotype; LDLR; APOB; PCSK9;
Keywords: PTP1B; protein tyrosine phosphatase 1B; CNS; central nervous system; HFD; high fat diet; NPY; neuropeptide Y; AMPK; 5' AMP-activated protein kinase; BAT; brown adipose tissue; AF; albiflorin; hAMSCs; human adipose tissue-derived mesenchymal stem cells; PP
Keywords: alirocumab; chronic kidney disease; impaired renal function; LDL-C; PCSK9; safety;
Keywords: 27-HC; 27-hydroxycholesterol; ER; estrogen receptor; CYP27A1; cytochrome P450, family 27, subfamily A, polypeptide 1; LXR; liver X receptor; BRCA1 and BRCA2; Breast cancer 1 and 2; LDL; low density lipoprotein; HDL; high density lipoprotein; ApoE; apolipo
Keywords: Rare disease; Sterol; Homeostasis; Sterol regulatory element binding protein-2; ABCG8; ATP-binding cassette sub-family G member 8; SREBP-2; Sterol regulatory element-binding protein 2; LDL; low-density lipoprotein; HMGCR; 3-Hydroxy-3-Methylglutaryl-CoA re
Keywords: ANCHOR; Effect of AMR101 (Icosapent Ethyl) on Triglyceride Levels in Patients on Statins With High Triglyceride Levels (â¥200 and <500â¯mg/dL); Apo; apolipoprotein; ASAP; Antioxidant Supplementation in Atherosclerosis Prevention; CANTOS; Canakinumab Ant
Keywords: ADP; adenosine diphosphate; Apo; apolipoprotein; AT III; antithrombin III; AUC; area under the curve; BMI; body mass index; CET; cholesterol ester transfer; CRP; C-reactive protein; CVD; cardiovascular disease; FMD; flow mediated dilation; FVII; factor VI
Keywords: Ang-II; angiotensin-II; CDKs; cyclin-dependent kinases; ChGn; chondroitin N-acetylgalactosaminyltransferase; ChPF; chondroitin polymerizing factor; ChSy; chondroitin synthase; CS; chondroitin sulfate; CVDs; cardiovascular diseases; C4S; chondroitin-4-sulf
Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients: A randomised controlled trial
Keywords: Lupin protein; Lipids; PCSK9; Blood pressure; Glycaemic control; ACE; angiotensin converting enzyme; ApoA-I; apolipoprotein A-I; ApoB; apolipoprotein B; BMI; body mass index; BP; blood pressure; CK; creatine kinase; CRP; C-reactive protein; CV; cardiovasc
Keywords: Lp(a); lipoprotein(a); LDL; low-density lipoprotein; apoB100; apolipoprotein B100; apo(a); apolipoprotein(a); CVD; cardiovascular disease; LDL-C; LDL-cholesterol; HDL-C; high-density lipoprotein cholesterol; K; kringle; PCSK9; proprotein covertase subtili
Keywords: Atherosclerosis; Brown adipose tissue; Hypercholesterolemia; Cholesterol metabolism; Lipid and lipoprotein metabolism; ApoE; apolipoprotein E; β3-AR; β3-adrenergic receptor; (i)BAT; (interscapular) brown adipose tissue; (T)C; (total) cholesterol; CETP;
Keywords: Familial hypercholesterolemia; Mutation spectrum; LDLR; APOB; PCSK9;
Keywords: PCSK9; LDL-C; Familial hypercholesterolemia; Safety; Tolerability; Monoclonal antibody;
Keywords: Hypercholesterolemia; Genetics; Cardiovascular; PCSK9; Clinical trial; LDLR; APOB;
Keywords: Alirocumab; PCSK9; LDL-C; HeFH; Lipid therapy; Cholesterol; Maximally tolerated statin; Lipid lowering; Placebo-controlled; Double-blind;
Keywords: Animal models; Atherosclerosis; Plaque rupture; ApoE; LDL receptor; PCSK9;
Keywords: SCFAs; short-chain fatty acids; LDLR; low-density lipoprotein receptor; InsR; insulin receptor; AMPK; AMP-activated protein kinase; PCSK9; proprotein convertase subtilisin kexin 9; PTP1B; protein tyrosine phosphatase 1B; BBR; berberine; TC; total choleste
Keywords: PCSK9; Carotid IMT and Cardiovascular disease
Keywords: FH; familial hypercholesterolemia; SNP; single nucleotide polymorphism; PCSK9; protein convertase subtilisin/kexin 9 gene; APOB; apolipoprotein B gene; Familial hypercholesterolemia; LDLR mutation; LDL-C gene score;
Keywords: Atherosclerosis; Hypertension; PCSK9;
Keywords: cardiovascular drug development; regulatory science; translational researchATC, Anatomical Therapeutic Chemical; CI, confidence interval; CNS, central nervous system; FDA, Food and Drug Administration; HR, hazard ratio; LDL, low-density lipoprotein; PCSK9
Keywords: APOB; Familial hypercholesterolemia; Genetics; Greek; LDLR; Mutations; PCSK9;
Keywords: PCSK9; Cardiovascular risk; Mortality; Lipids; Meta-analysis;
Keywords: ACC/AHA; American College of Cardiology/American Heart Association; ApoB; apolipoprotein B; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; DLCN; Dutch Lipid Clinic Network; FAMCAT; an FH prediction model; FDA; Food and Drug Ad
Keywords: Alzheimer's disease; Aβ; Cholesterol; apoE; PCSK9; LRP1;
Keywords: Atherogenesis; Carnitine; PCSK9; Statin; Coenzyme A; Cholesterol synthesis; HDL; LDL; Fcγ;
Keywords: Familial hypercholesterolemia; LDL cholesterol; Electronic health record; PCSK9; Statin;
Keywords: Monoclonal antibodies; Tocilizumab; Alirocumab; Evolocumab; Reticuloendothelial system; IL-6; PCSK9; Methotrexate; Simvastatin;
Keywords: Statin intolerance; Myalgias; Myopathy; PCSK9 inhibitors; ACC/AHA; American College of Cardiology/American Heart Association; ASCVD; Atherosclerotic cardiovascular disease; CoQ10; Coenzyme Q 10; CK; Creatine Kinase; FDA; Federal Drug Administration; HMG-C
Keywords: Biacore; ProteOn; Octet; MX96; Antibody-antigen interactions; Optical biosensor; mAb; monoclonal antibody; SPR; surface plasmon resonance; BLI; Bio-Layer Interferometry; CFM; continuous flow microfluidics; PCSK9; proprotein convertase substilisin kexin ty
Keywords: Statin; Non-adherence; Discontinuation; PCSK9; HDL-C; Statin-associated muscle symptoms; Cardiovascular risk;
Keywords: Acat2; cholesterolacyl transferase 2; ALT; alanine aminotransferase; AST; aspartate aminotransferase; Bax; Bcl-2-associated x protein; BUN; blood urea nitrogen; CREA; creatinine; DBIL; direct bilirubin; DMEM; Dulbecco's modified eagle medium; Gclc; glut
Keywords: CETP; LPL; LIPC; PCSK9; Lipid profile;
Keywords: APEX; arrayed primer extension; apoB-100; apolipoprotein B-100; apoE; apolipoprotein E; CETP; cholesteryl ester transfer protein; CVDs; cardiovascular diseases; DGGE; denaturing gradient gel electrophoresis; DHPLC; denaturing high performance liquid chrom
Keywords: Familial hypercholesterolemia; Diagnostic tools; Functional assay; Mutation pathogenicity; LDLR; APOB; PCSK9; ADH; autosomal dominant hypercholesterolemia; FH; familial hypercholesterolemia; LDLR; LDL receptor; APOB; apolipoprotein B-100; PCSK9; proprotei
Keywords: PCSK9; Lipoprotein subfractions; Low density lipoprotein cholesterol; Intermediate density lipoproteins; Nuclear magnetic resonance spectroscopy;
Keywords: Statins; Resistance; Intolerance; LDL-cholesterol; Ezetimibe; PCSK9
Keywords: atherosclerotic plaque; imaging; inflammation; PCSK9; statinsACS, acute coronary syndrome(s); CAD, coronary artery disease; CI, confidence interval; HDL-C, high-density lipoprotein-cholesterol; IL, interleukin; IVUS, intravascular ultrasound; LDL-C, low-d
Keywords: Statin; LDL-C; Ezetimibe; Niacin; Fibrate; Combination therapy; PCSK9;
Keywords: AAV1; adeno-associated virus serotype 1; ACC; American College of Cardiology; ACCELERATE; A Study of Evacetrapib in High-Risk Vascular Disease; ACCORD; Action to Control Cardiovascular Risk in Diabetes; ADA; American Diabetes Association; AMP; adenosine m
Keywords: ALAS1; δ-aminolevulinate synthase 1; ANGPTL3; angiopoietin-like 3; FVII; factor VII; FXI; factor XI; GCGR; glucagon receptor; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; HoFH; homozygous familial hypercholesterolemia; KSP; kinesin spindle prot
Keywords: Autosomal dominant hypercholesterolemia; LDL receptor; Apolipoprotein B; PCSK9; Mutations;
Keywords: Familial hypercholesterolemia; LDLR; PCSK9; Xanthomas; HRM; Consanguinity;
Keywords: Lipid metabolism; Cholesterol; LDL; PCSK9; FCHL; FCHL; familial combined hyperlipidemia; LDLR; LDL receptor; PCSK9; proprotein convertase subtilisin kexin type 9; SREBP2; sterol regulatory element binding protein 2; LDL-C; LDL cholesterol; HDL-C; HDL chol
Keywords: CYP7A1; cytochrome P450 family 7 subfamily A polypeptide 1; FXRα; farnesoid X receptor α; HMGCR; 3-hydroxy-3-methylglutaryl-CoA reductase; LDLR; low density lipoprotein receptor; PCSK9; proprotein convertase subtilisin/kexin type 9; SREBP2; sterol regul
Keywords: Non-HDL-C, non-high density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ASCVD, atherosclerotic cardiovascular disease; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; SREBPs, sterol response element binding proteins; PCSK9
Keywords: PCSK9; Diet; Adipose tissue; Fatty acids; Fish oils
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis
Keywords: PCSK9; Acute coronary syndromes; Cardiovascular risk; Atherosclerosis; Carotid stenosis;